Orris

Modern Understanding and Diagnosis of Diabetes Insipidus

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

"diabetes insipidus" AND copeptin

Searching the Web

2025 diabetes insipidus diagnosis copeptin hypertonic saline guideline

Reading File
Reading File
Reading File
Reading Web Page

https://www.ncbi.nlm.nih.gov/books/NBK537591

Reading Article

PMID: 39409072

Modern Understanding and Diagnosis of Diabetes Insipidus

Topic map

  1. Modern terminology and physiology: arginine vasopressin (AVP) deficiency and AVP resistance
  2. Causes and classification: central AVP deficiency, nephrogenic AVP resistance, gestational DI, primary polydipsia
  3. Clinical recognition: polyuria, polydipsia, hypernatremia, dehydration risk
  4. Stepwise diagnosis: confirmation of hypotonic polyuria and exclusion of solute diuresis
  5. Dynamic testing: water-deprivation test plus desmopressin
  6. Modern biomarkers: baseline and stimulated copeptin, especially hypertonic-saline and arginine stimulation
  7. Etiologic work-up: medications, calcium/potassium, pituitary hormone testing, MRI of the hypothalamic-pituitary region
  8. Special settings: postoperative, pregnancy, children, impaired thirst, and hospitalized patients

High-level overview

Diabetes insipidus is now more accurately framed as a disorder of the AVP system, rather than simply “central” versus “nephrogenic” DI:
  • AVP deficiency: insufficient synthesis or secretion of AVP, formerly central or cranial DI.
  • AVP resistance: renal failure to respond appropriately to AVP, formerly nephrogenic DI.
  • These must be distinguished from primary polydipsia, in which excessive water intake suppresses AVP and produces dilute urine.
The diagnostic starting point is not a dynamic test. First establish true hypotonic polyuria: generally urine output >50 mL/kg/day with urine osmolality <300 mOsm/kg, while excluding glucose-driven osmotic diuresis, diuretic effects, renal dysfunction, hypercalcemia, and hypokalemia. Brenner and Rector’s The Kidney, p. 654.
A person who is hyperosmolar or hypernatremic but still produces inappropriately dilute urine has DI until proven otherwise. Desmopressin response can then help distinguish AVP deficiency from AVP resistance. A rise in urine osmolality >50% supports AVP deficiency; minimal change favors AVP resistance, though partial disease and chronic polyuria can make the traditional test difficult to interpret. Brenner and Rector’s The Kidney, p. 654.
The major modern advance is copeptin, a stable surrogate marker released in equimolar amounts with AVP. In specialized endocrine settings, a very high unstimulated copeptin supports AVP resistance, whereas stimulated copeptin after controlled hypertonic saline or arginine can distinguish partial AVP deficiency from primary polydipsia more accurately and often more tolerably than water deprivation. Hypertonic-saline testing needs close monitoring and is not suitable for unsupervised outpatient use. A recent pediatric systematic review found high pooled diagnostic accuracy for copeptin-based testing, while also noting that standardized pediatric protocols remain needed (2024 systematic review).
Modern nomenclature also matters because it directs the etiologic search: AVP deficiency may follow pituitary surgery, trauma, tumors, infiltrative or autoimmune disease, and genetic disorders. AVP resistance is often medication-related, particularly lithium, or associated with hypercalcemia, hypokalemia, kidney disease, or inherited AVPR2/AQP2 defects. Harrison’s Principles of Internal Medicine, 22nd ed., p. 3060.
Which area should I develop into a detailed exam-style note?

Create an exam-style diagnostic algorithm for AVP disorders

Reading File
Finding Sources
Finding Sources
Searching PubMed

"arginine vasopressin deficiency" AND copeptin

Searching the Web

Endotext 2025 diagnostic tests diabetes insipidus copeptin 6.5 pmol algorithm

Exam-Style Diagnostic Algorithm for AVP Disorders

AVP disorders include:
  • AVP deficiency (AVP-D): formerly central or cranial diabetes insipidus
  • AVP resistance (AVP-R): formerly nephrogenic diabetes insipidus
  • Primary polydipsia (PP): the principal mimic
  • Gestational AVP-D: increased placental vasopressinase activity during pregnancy
PATIENT WITH POLYURIA ± POLYDIPSIA
                  ↓
1. CONFIRM TRUE POLYURIA
   • 24-h urine volume >50 mL/kg/day
     (or approximately >3 L/day in adults)
                  ↓
2. IS THE URINE HYPOTONIC?
   • Urine osmolality (Uosm) <300 mOsm/kg
                  ↓
       ┌──────────┴──────────┐
       │                     │
Uosm ≥300 mOsm/kg       Uosm <300 mOsm/kg
Consider solute          HYPOTONIC POLYURIA:
diuresis, e.g.:          suspect AVP disorder or PP
• Diabetes mellitus                  ↓
• Mannitol                            ↓
• High urea load
• Diuretics
• Recovery from AKI
                  ↓
3. EXCLUDE COMMON REVERSIBLE CAUSES
   • Serum glucose and HbA1c
   • Urea, creatinine/eGFR
   • Sodium, potassium, calcium
   • Urinalysis, medication history
   • Look for lithium, demeclocycline, cisplatin,
     amphotericin B, loop diuretics
                  ↓
4. ASSESS SERUM SODIUM / PLASMA OSMOLALITY

Step 4: Initial biochemical separation

A. Plasma osmolality high or serum Na+ ≥146 mmol/L
   + urine remains inappropriately dilute
   → DIAGNOSIS: AVP DISORDER IS VERY LIKELY
   → Primary polydipsia is unlikely
                    ↓
   Differentiate AVP-D from AVP-R

B. Plasma osmolality normal or low-normal
   + hypotonic polyuria
   → AVP-D, partial AVP-R, and primary polydipsia remain possible
                    ↓
   Proceed to copeptin-based testing if available
   OR supervised water-deprivation test plus desmopressin
Hypernatremia with inadequately concentrated urine is strongly suggestive of DI because normal thirst usually prevents hypernatremia in ambulatory patients with intact access to water. Brenner and Rector’s The Kidney, p. 654.

Preferred modern pathway: Copeptin-based diagnosis

CONFIRMED HYPOTONIC POLYURIA
                  ↓
Measure BASELINE PLASMA COPEPTIN
                  ↓
┌─────────────────────────────────────────────────────┐
│ Copeptin ≥21.4 pmol/L                               │
│ → AVP RESISTANCE (nephrogenic DI)                   │
│   is strongly supported                             │
└─────────────────────────────────────────────────────┘
                  ↓
If baseline copeptin is not diagnostic
                  ↓
HYPERTONIC SALINE-STIMULATED COPEPTIN
in a specialist, closely monitored setting
                  ↓
Achieve adequate osmotic stimulation
(commonly serum Na+ ≥150 mmol/L)
                  ↓
┌─────────────────────────────────────────────────────┐
│ Stimulated copeptin low: ≤4.9 pmol/L                │
│ → AVP DEFICIENCY                                    │
│    complete or partial                              │
├─────────────────────────────────────────────────────┤
│ Stimulated copeptin >4.9 pmol/L                     │
│ → PRIMARY POLYDIPSIA favored                        │
└─────────────────────────────────────────────────────┘
Some newer protocols use a higher stimulated threshold, such as 6.5 pmol/L, depending on the assay and protocol. Use local endocrine-laboratory validation rather than applying a cutoff blindly.
A copeptin >4.9 pmol/L after hypertonic saline at serum sodium ≥150 mmol/L supports primary polydipsia, with reported diagnostic accuracy of 96.5% in the difficult AVP-D versus primary-polydipsia distinction. Harrison’s Principles of Internal Medicine, 22nd ed., p. 3060. The Endotext diagnostic review describes hypertonic-saline-stimulated copeptin as the most accurate assessment, but it requires serial sodium monitoring.
Do not perform hypertonic saline testing unsupervised. Avoid or use particular caution in heart failure, uncontrolled hypertension, seizure disorders, and patients unable to communicate thirst or symptoms.

Alternative pathway: Water-deprivation test plus desmopressin

Use when copeptin testing is unavailable, or where a specialist chooses this established approach.
SUPERVISED WATER-DEPRIVATION TEST
                  ↓
Monitor:
• Weight
• Blood pressure and pulse
• Serum sodium / plasma osmolality
• Urine volume and urine osmolality
                  ↓
STOP if:
• Significant weight loss
• Rising serum sodium / osmolality
• Hypotension, tachycardia, severe symptoms
                  ↓
Give desmopressin
                  ↓
Measure change in urine osmolality
ResultLikely diagnosis
Urine concentrates appropriately during water deprivation, often Uosm >500-800 mOsm/kgPrimary polydipsia or normal physiology
Urine remains dilute during deprivation, then Uosm rises >50% after desmopressinComplete AVP deficiency
Urine remains dilute, then rises <10% after desmopressinAVP resistance
Intermediate concentration or desmopressin response, often 10%-50%Partial AVP deficiency, partial AVP resistance, or chronic primary polydipsia: use stimulated copeptin if possible
In established hyperosmolality, an increase in Uosm >50% after desmopressin reliably supports AVP deficiency, while <10% supports AVP resistance. Intermediate responses are not definitive. Brenner and Rector’s The Kidney, p. 654.

Etiologic Work-up After Classification

If AVP deficiency is diagnosed

AVP DEFICIENCY
      ↓
History and examination
      ↓
• Recent pituitary/hypothalamic surgery?
• Head trauma?
• Postpartum disease?
• Headache, visual field loss, cranial neuropathy?
• Autoimmune/inflammatory or infiltrative disease?
• Childhood onset or family history?
      ↓
Tests
• MRI hypothalamus-pituitary region with contrast
• Anterior pituitary hormone assessment
• Consider tumor, metastasis, germinoma, craniopharyngioma,
  sarcoidosis, Langerhans-cell histiocytosis, hypophysitis,
  infection, trauma, genetic AVP disorders

If AVP resistance is diagnosed

AVP RESISTANCE
      ↓
Review reversible causes first
      ↓
• Lithium exposure
• Hypercalcemia
• Hypokalemia
• Chronic kidney disease
• Obstructive uropathy
• Drugs: demeclocycline, amphotericin B, cisplatin, etc.
      ↓
If early-onset, severe, or family history:
• Consider inherited AVPR2 mutation, often X-linked
• Consider AQP2 mutation

If primary polydipsia is diagnosed

PRIMARY POLYDIPSIA
      ↓
Assess:
• Psychiatric illness or psychotropic drugs
• Compulsive water drinking
• Hypothalamic/dipsogenic thirst disorder
• “Health” or lifestyle-driven excessive intake
      ↓
Check for:
• Hyponatremia
• Low plasma osmolality
• Risk from empiric desmopressin

High-yield exam points

  1. First prove hypotonic polyuria. Do not label DI solely because the patient reports frequent urination.
  2. Exclude osmotic diuresis first, especially diabetes mellitus and diuretic-related polyuria.
  3. High plasma osmolality or hypernatremia plus dilute urine strongly indicates DI.
  4. Copeptin is preferred over direct AVP measurement because it is more stable and easier to measure reliably.
  5. Baseline copeptin ≥21.4 pmol/L strongly supports AVP resistance.
  6. Low stimulated copeptin supports AVP deficiency; an appropriate stimulated rise supports primary polydipsia.
  7. Water deprivation is less reliable in partial disorders and in long-standing primary polydipsia, because chronic excess water can blunt medullary concentrating capacity.
  8. Never give desmopressin empirically to presumed primary polydipsia without appropriate assessment, because water retention may cause dangerous hyponatremia.
  9. After AVP deficiency is established, evaluate for hypothalamic-pituitary structural disease and anterior pituitary dysfunction.
  10. In pregnancy, consider gestational AVP deficiency due to increased vasopressinase, particularly when symptoms begin in late pregnancy and remit postpartum.
Terminology update: the modern labels AVP deficiency and AVP resistance better identify the underlying pathophysiology than “central” and “nephrogenic” DI. Harrison’s Principles of Internal Medicine, 22nd ed., p. 3060.

Understanding and Diagnosis of diabetes incipidus

Reading File
Finding Sources
Finding Sources
Searching PubMed

"diabetes insipidus" AND copeptin

Searching the Web

2025 Endotext diagnostic tests diabetes insipidus copeptin water deprivation

Understanding and Diagnosis of Diabetes Insipidus

Definition

Diabetes insipidus (DI) is a disorder of water balance characterized by the passage of large volumes of dilute urine due to impaired action of arginine vasopressin (AVP), also called antidiuretic hormone.
Modern terminology:
  • AVP deficiency (AVP-D): inadequate AVP synthesis or release. Formerly called central, cranial, or neurogenic DI.
  • AVP resistance (AVP-R): kidneys do not respond adequately to AVP. Formerly called nephrogenic DI.
  • Primary polydipsia (PP): excessive water intake suppresses AVP secretion and mimics DI, but is not an AVP disorder.

Normal physiology

AVP is synthesized in the hypothalamus, transported to the posterior pituitary, and released mainly in response to:
  1. Increased plasma osmolality
  2. Reduced effective circulating volume or blood pressure
At the renal collecting duct, AVP binds to the V2 receptor, causing insertion of aquaporin-2 water channels into the luminal membrane. Water is reabsorbed, urine becomes concentrated, and plasma osmolality falls.
↑ Plasma osmolality / ↓ effective circulating volume
                    ↓
              ↑ AVP release
                    ↓
       V2 receptor in collecting duct
                    ↓
       Aquaporin-2 insertion into membrane
                    ↓
          ↑ Water reabsorption
                    ↓
           Concentrated urine
In DI, this mechanism fails, so the kidney excretes dilute urine despite a need to conserve water.

Classification and causes

DisorderBasic defectImportant causes
AVP deficiencyReduced AVP secretionPituitary surgery, head injury, hypothalamic-pituitary tumor, craniopharyngioma, germinoma, metastasis, autoimmune hypophysitis, sarcoidosis, Langerhans-cell histiocytosis, infection, genetic disease, idiopathic disease
AVP resistanceRenal unresponsiveness to AVPLithium, hypercalcemia, hypokalemia, chronic kidney disease, obstructive uropathy, inherited AVPR2 or AQP2 mutations
Gestational DIExcess AVP degradation by placental vasopressinaseUsually develops in late pregnancy and often resolves after delivery
Primary polydipsiaExcess water intake suppresses AVPPsychiatric illness, compulsive water drinking, hypothalamic thirst disorders, medication-related dry mouth, excessive “healthy” water consumption
Harrison’s Principles of Internal Medicine, 22nd ed., p. 3060.

Clinical features

Typical symptoms

  • Polyuria, often including nocturia
  • Polydipsia, with a preference for cold water
  • Passage of very dilute urine
  • Fatigue, poor concentration, constipation, or postural symptoms if water intake is inadequate

Features suggesting significant DI

  • Hypernatremia
  • Raised plasma osmolality
  • Dehydration
  • Hypotension, tachycardia
  • Confusion, irritability, seizures, or reduced consciousness in severe hypernatremia
Patients with intact thirst and access to water may maintain near-normal sodium levels despite substantial DI. Hypernatremia becomes more likely in infants, frail older adults, unconscious patients, those with impaired thirst, and hospitalized patients unable to access water.

Diagnostic approach

Step 1: Confirm true polyuria

Do not confuse polyuria with urinary frequency.
  • Polyuria: increased urine volume
  • Frequency: frequent voiding of small volumes
A practical adult threshold is:
  • Urine output >3 L/day, or
  • >50 mL/kg/day on a 24-hour collection

Step 2: Establish hypotonic polyuria

Measure:
  • Urine osmolality
  • Serum sodium
  • Plasma osmolality
  • Serum glucose
  • Urea, creatinine, calcium, potassium
  • Urinalysis and, when relevant, urine glucose
Hypotonic polyuria is generally:
  • Large urine output, plus
  • Urine osmolality <300 mOsm/kg
Before considering DI, rule out solute diuresis, such as:
  • Diabetes mellitus with glycosuria
  • Mannitol use
  • High urea load
  • Diuretics
  • Recovery phase of acute kidney injury
  • Chronic kidney disease
A 24-hour urine volume >50 mL/kg with urine osmolality <300 mOsm/kg supports hypotonic polyuria. Brenner and Rector’s The Kidney, p. 654.

Step 3: Interpret serum sodium and plasma osmolality

FindingInterpretation
High serum sodium or high plasma osmolality with dilute urineDI is strongly likely
Normal sodium and normal plasma osmolalityPartial DI or primary polydipsia possible
Low-normal sodium or low plasma osmolalityPrimary polydipsia more likely
High plasma osmolality or hypernatremia with inappropriately dilute urine is a major diagnostic clue for DI. Primary polydipsia is unlikely in this setting.

Diagnostic Algorithm

POLYURIA ± POLYDIPSIA
          ↓
Confirm increased 24-hour urine volume
          ↓
Measure urine osmolality
          ↓
 ┌─────────────────────────────────────────────┐
 │ Urine osmolality ≥300 mOsm/kg               │
 │ → Consider solute diuresis or renal disease │
 └─────────────────────────────────────────────┘
          ↓
 ┌─────────────────────────────────────────────┐
 │ Urine osmolality <300 mOsm/kg               │
 │ → Hypotonic polyuria                        │
 └─────────────────────────────────────────────┘
          ↓
Check serum sodium and plasma osmolality
          ↓
 ┌─────────────────────────────────────────────┐
 │ Hypernatremia / hyperosmolality             │
 │ + inappropriately dilute urine              │
 │ → DI strongly suspected                     │
 └─────────────────────────────────────────────┘
          ↓
Differentiate AVP deficiency from AVP resistance
with copeptin or desmopressin-based testing
          ↓
Normal or low-normal sodium/osmolality
          ↓
Differentiate partial AVP deficiency,
partial AVP resistance, and primary polydipsia
with stimulated copeptin or water-deprivation test

Differentiating AVP deficiency, AVP resistance, and primary polydipsia

A. Copeptin-based testing: modern preferred approach

Copeptin is the C-terminal fragment of the AVP precursor. It is released in equimolar quantities with AVP but is much more stable and easier to measure than AVP itself.

Baseline copeptin

  • Baseline copeptin ≥21.4 pmol/L strongly supports AVP resistance
  • A very low baseline value, especially during hyperosmolality, supports complete AVP deficiency
  • Intermediate levels need dynamic stimulation

Hypertonic-saline-stimulated copeptin

In a monitored specialist setting, hypertonic saline raises serum sodium and should stimulate AVP and copeptin release in normal individuals and in primary polydipsia.
Stimulated copeptin resultInterpretation
Low, ≤4.9 pmol/LAVP deficiency likely
>4.9 pmol/L after adequate hyperosmolar stimulationPrimary polydipsia favored
Baseline ≥21.4 pmol/LAVP resistance strongly favored
A stimulated copeptin >4.9 pmol/L when serum sodium reaches at least 150 mmol/L supports primary polydipsia and has reported accuracy of about 96.5% for differentiating it from AVP deficiency. Harrison’s Principles of Internal Medicine, 22nd ed., p. 3060.
Hypertonic saline testing requires frequent sodium monitoring and is performed only under expert supervision. The Endotext diagnostic review describes it as the most accurate dynamic assessment, while noting that access to copeptin testing and safe testing expertise varies by center.

B. Water-deprivation test plus desmopressin

This remains an important alternative where copeptin testing is not available.

Principle

Water deprivation should normally increase plasma osmolality, stimulate AVP release, and lead to concentrated urine. After dehydration, desmopressin is administered to test the renal response.

Typical interpretation

ResultMost likely diagnosis
Urine becomes appropriately concentrated with water deprivation, often >500-800 mOsm/kgPrimary polydipsia or normal physiology
Urine remains dilute, then rises >50% after desmopressinComplete AVP deficiency
Urine remains dilute, then rises <10% after desmopressinAVP resistance
Intermediate responsePartial AVP deficiency, partial AVP resistance, or chronic primary polydipsia
A response in urine osmolality of >50% after desmopressin supports AVP deficiency, while a response <10% supports AVP resistance. Intermediate responses are difficult to classify and should prompt specialist assessment, often with copeptin testing. Brenner and Rector’s The Kidney, p. 654.

Limitations

The traditional water-deprivation test is less reliable in:
  • Partial AVP deficiency
  • Partial AVP resistance
  • Long-standing primary polydipsia
  • Chronic kidney disease
  • Patients with impaired thirst
  • Young children or patients unable to tolerate dehydration
Long-term excessive water intake can wash out the medullary concentration gradient and reduce aquaporin-2 expression, causing an equivocal response that can resemble partial AVP deficiency.

Etiological investigations

In confirmed AVP deficiency

Perform:
  • MRI of the hypothalamic-pituitary region with contrast
  • Assessment of anterior pituitary function
  • Visual-field assessment if a sellar or suprasellar lesion is suspected
  • Review for pituitary surgery, head injury, malignancy, inflammatory disease, and infiltrative disease
  • Genetic evaluation in childhood-onset or familial cases
Important causes to seek include craniopharyngioma, germinoma, metastasis, autoimmune hypophysitis, sarcoidosis, Langerhans-cell histiocytosis, infection, trauma, and prior pituitary surgery.

In confirmed AVP resistance

Review for:
  • Lithium exposure
  • Hypercalcemia
  • Hypokalemia
  • Obstructive uropathy
  • Chronic kidney disease
  • Medications such as demeclocycline, amphotericin B, and cisplatin
  • Family history of inherited nephrogenic DI
Inherited AVP resistance is commonly due to AVPR2 mutations and is often X-linked. Less commonly, it results from AQP2 mutations.

Key distinctions for exams

FeatureAVP deficiencyAVP resistancePrimary polydipsia
AVP actionInadequate secretionKidney does not respondPhysiologically suppressed
Serum sodiumOften high if unable to drinkOften high if unable to drinkOften low-normal
Baseline copeptinLow or inappropriately normalHighUsually low-normal
Response to desmopressinMarked rise in UosmLittle or no rise in UosmUsually little additional rise after adequate deprivation
MRI pituitaryMay show stalk lesion or absent posterior bright spotUsually normalUsually normal
Main treatment principleAVP replacement and treat causeCorrect cause, reduce solute load, support water balanceAddress excess fluid intake and cause

Important safety note

Suspected DI with confusion, severe dehydration, hypernatremia, inability to drink, vomiting, altered consciousness, or recent pituitary surgery requires urgent medical assessment. Dynamic diagnostic testing and desmopressin use should be directed by an endocrinology or experienced medical team, because inappropriate desmopressin in primary polydipsia can cause severe hyponatremia.

Can u give me detail ppt for presentation on this topic with suitable images

Reading File
Reading File
Finding Sources
Finding Sources
Searching Images

diagram hypothalamus posterior pituitary vasopressin synthesis transport release anatomy

Searching Images

kidney collecting duct vasopressin V2 receptor aquaporin 2 diagram

Searching Images

MRI central diabetes insipidus pituitary stalk thickening posterior pituitary bright spot

This diagnostic image set consists of six magnetic resonance imaging (MRI) panels of the hypothalamic-pituitary region, illustrating the progression of lymphocytic infundibuloneurohypophysitis (LINH). Panels A-C represent the initial presentation: Coronal (A) and sagittal (B) T1-weighted images show significant thickening of the pituitary stalk (arrows) and the pathognomonic absence of the posterior pituitary 'bright spot' (arrowhead in B). Panel C is a contrast-enhanced T1 image showing rapid enhancement of the enlarged stalk. Panels D-F show a one-year follow-up: There is visible spontaneous regression of the pituitary stalk thickening (arrows in D, E, and F), indicating the self-limiting nature of the inflammatory process. However, sagittal T1-weighted images (E) confirm the persistent absence of the posterior pituitary bright spot (arrowhead), which correlates clinically with chronic central diabetes insipidus. This comparison chart serves as a primary educational tool for identifying the radiological hallmarks of infundibulitis and differentiating spontaneous structural resolution from functional recovery in neuroendocrine disorders.

This diagnostic image set consists of six magnetic resonance imaging (MRI) panels of the hypothalamic-pituitary region, illustrating the progression of lymphocytic infundibuloneurohypophysitis (LINH). Panels A-C represent the initial presentation: Coronal (A) and sagittal (B) T1-weighted images show significant thickening of the pituitary stalk (arrows) and the pathognomonic absence of the posterior pituitary 'bright spot' (arrowhead in B). Panel C is a contrast-enhanced T1 image showing rapid enhancement of the enlarged stalk. Panels D-F show a one-year follow-up: There is visible spontaneous regression of the pituitary stalk thickening (arrows in D, E, and F), indicating the self-limiting nature of the inflammatory process. However, sagittal T1-weighted images (E) confirm the persistent absence of the posterior pituitary bright spot (arrowhead), which correlates clinically with chronic central diabetes insipidus. This comparison chart serves as a primary educational tool for identifying the radiological hallmarks of infundibulitis and differentiating spontaneous structural resolution from functional recovery in neuroendocrine disorders.

This composite of magnetic resonance imaging (MRI) frames focuses on the sellar and suprasellar regions, specifically the pituitary gland and stalk (infundibulum), over a 15-month progression. Panels (a, d) show sagittal and coronal non-contrast T1-weighted images at baseline, where the bright spot of the posterior pituitary is absent. Panels (b, e) demonstrate homogeneous gadolinium enhancement of the pituitary at initial presentation. By 15 months (c, f), contrast-enhanced images reveal a hypoenhancing area within the thickened pituitary stalk extending toward the posterior lobe. The bottom row (g-j) provides a serial sagittal plain T1-weighted timeline (at 0, 6, 12, and 15 months), illustrating the progressive morphological change from a thin, linear stalk to a significantly thickened, bulbous infundibulum. These imaging features—loss of the posterior bright spot, progressive infundibular thickening, and late-stage hypoenhancement—are indicative of an infiltrative or neoplastic process such as a central nervous system germinoma or lymphocytic infundibuloneurohypophysitis, clinically manifesting as central diabetes insipidus.

This composite of magnetic resonance imaging (MRI) frames focuses on the sellar and suprasellar regions, specifically the pituitary gland and stalk (infundibulum), over a 15-month progression. Panels (a, d) show sagittal and coronal non-contrast T1-weighted images at baseline, where the bright spot of the posterior pituitary is absent. Panels (b, e) demonstrate homogeneous gadolinium enhancement of the pituitary at initial presentation. By 15 months (c, f), contrast-enhanced images reveal a hypoenhancing area within the thickened pituitary stalk extending toward the posterior lobe. The bottom row (g-j) provides a serial sagittal plain T1-weighted timeline (at 0, 6, 12, and 15 months), illustrating the progressive morphological change from a thin, linear stalk to a significantly thickened, bulbous infundibulum. These imaging features—loss of the posterior bright spot, progressive infundibular thickening, and late-stage hypoenhancement—are indicative of an infiltrative or neoplastic process such as a central nervous system germinoma or lymphocytic infundibuloneurohypophysitis, clinically manifesting as central diabetes insipidus.

Diagnostic Magnetic Resonance Imaging (MRI) of the brain focusing on the sella turcica and pituitary region. Figure (a) is a sagittal T1-weighted image demonstrating a thickened pituitary stalk (infundibulum), indicated by a blue arrow. Notably, there is an absence of the normal T1-weighted hyperintense 'bright spot' of the posterior pituitary gland (neurohypophysis). Figure (b) provides a coronal T1-weighted view with gadolinium contrast enhancement, further highlighting the nodular thickening and pathological enhancement of the pituitary stalk (black arrow). Surrounding anatomical structures including the anterior pituitary, optic chiasm, sphenoid sinus, and cavernous sinuses are visible. These visual findings are characteristic of infundibuloneurohypophysitis, often associated with systemic conditions such as Langerhans cell histiocytosis, and frequently correlate with clinical symptoms of central diabetes insipidus.

Diagnostic Magnetic Resonance Imaging (MRI) of the brain focusing on the sella turcica and pituitary region. Figure (a) is a sagittal T1-weighted image demonstrating a thickened pituitary stalk (infundibulum), indicated by a blue arrow. Notably, there is an absence of the normal T1-weighted hyperintense 'bright spot' of the posterior pituitary gland (neurohypophysis). Figure (b) provides a coronal T1-weighted view with gadolinium contrast enhancement, further highlighting the nodular thickening and pathological enhancement of the pituitary stalk (black arrow). Surrounding anatomical structures including the anterior pituitary, optic chiasm, sphenoid sinus, and cavernous sinuses are visible. These visual findings are characteristic of infundibuloneurohypophysitis, often associated with systemic conditions such as Langerhans cell histiocytosis, and frequently correlate with clinical symptoms of central diabetes insipidus.

This composite diagnostic image features two MRI sequences of the brain in a patient diagnosed with Erdheim-Chester disease. Panel A is an axial Fluid-Attenuated Inversion Recovery (FLAIR) MRI showing a discrete, nodular hyperintensity within the subcortical white matter of the right frontal lobe (indicated by a blue arrow). Panel B is a midline sagittal T1-weighted MRI focusing on the sella turcica and hypothalamo-pituitary axis. The blue arrow in Panel B highlights the pathological loss of the normal physiological hyperintense signal (the posterior pituitary 'bright spot') within the neurohypophysis, a finding often associated with central diabetes insipidus. The pituitary stalk appears normal in morphology without thickening. These neuroimaging findings demonstrate the multi-systemic central nervous system involvement of Erdheim-Chester disease, specifically manifesting as white matter parenchymal lesions and hypothalamic-pituitary infiltration.

This composite diagnostic image features two MRI sequences of the brain in a patient diagnosed with Erdheim-Chester disease. Panel A is an axial Fluid-Attenuated Inversion Recovery (FLAIR) MRI showing a discrete, nodular hyperintensity within the subcortical white matter of the right frontal lobe (indicated by a blue arrow). Panel B is a midline sagittal T1-weighted MRI focusing on the sella turcica and hypothalamo-pituitary axis. The blue arrow in Panel B highlights the pathological loss of the normal physiological hyperintense signal (the posterior pituitary 'bright spot') within the neurohypophysis, a finding often associated with central diabetes insipidus. The pituitary stalk appears normal in morphology without thickening. These neuroimaging findings demonstrate the multi-systemic central nervous system involvement of Erdheim-Chester disease, specifically manifesting as white matter parenchymal lesions and hypothalamic-pituitary infiltration.

This diagnostic imaging composite displays two T1-weighted magnetic resonance imaging (MRI) scans of the brain focusing on the sellar and suprasellar regions. Image A is a coronal view highlighting a diffuse, bulbous thickening of the pituitary infundibulum (indicated by a white arrow), which appears isointense to slightly hyperintense compared to the surrounding brain parenchyma. Image B is a sagittal view demonstrating the absence of the normal physiological 'posterior pituitary bright spot' (indicated by a blue arrow) within the sella turcica. These radiographic findings are characteristic of pituitary stalk lesions and are clinically significant in the diagnostic evaluation of central diabetes insipidus and intracranial germinomas. The visual data is optimized for teaching medical professionals about neuroendocrine anatomy, infundibular pathology, and the interpretation of gadolinium-enhanced or T1-weighted neuroradiological features.

This diagnostic imaging composite displays two T1-weighted magnetic resonance imaging (MRI) scans of the brain focusing on the sellar and suprasellar regions. Image A is a coronal view highlighting a diffuse, bulbous thickening of the pituitary infundibulum (indicated by a white arrow), which appears isointense to slightly hyperintense compared to the surrounding brain parenchyma. Image B is a sagittal view demonstrating the absence of the normal physiological 'posterior pituitary bright spot' (indicated by a blue arrow) within the sella turcica. These radiographic findings are characteristic of pituitary stalk lesions and are clinically significant in the diagnostic evaluation of central diabetes insipidus and intracranial germinomas. The visual data is optimized for teaching medical professionals about neuroendocrine anatomy, infundibular pathology, and the interpretation of gadolinium-enhanced or T1-weighted neuroradiological features.

This diagnostic image is a T1-weighted sagittal MRI of the brain, focused on the sellar and suprasellar regions. The central focus, highlighted by a white circle, demonstrates two primary pathological findings consistent with neurohypophysitis. First, there is a visible thickening of the pituitary stalk (infundibulum), measured at a maximum diameter of 4 mm. Second, the image shows the absence of the normal 'posterior pituitary bright spot,' which typically represents the hyperintense signal of stored vasopressin in the neurohypophysis on T1 sequences. The surrounding anatomical structures, including the optic chiasm, corpus callosum, and sphenoid sinus, are visible for orientation. These neuroradiological features are clinically significant for the diagnosis of central diabetes insipidus (CDI), illustrating the inflammatory involvement of the infundibulo-hypophyseal axis.

This diagnostic image is a T1-weighted sagittal MRI of the brain, focused on the sellar and suprasellar regions. The central focus, highlighted by a white circle, demonstrates two primary pathological findings consistent with neurohypophysitis. First, there is a visible thickening of the pituitary stalk (infundibulum), measured at a maximum diameter of 4 mm. Second, the image shows the absence of the normal 'posterior pituitary bright spot,' which typically represents the hyperintense signal of stored vasopressin in the neurohypophysis on T1 sequences. The surrounding anatomical structures, including the optic chiasm, corpus callosum, and sphenoid sinus, are visible for orientation. These neuroradiological features are clinically significant for the diagnosis of central diabetes insipidus (CDI), illustrating the inflammatory involvement of the infundibulo-hypophyseal axis.

Searching PubMed

"diabetes insipidus" AND copeptin

Searching the Web

2025 Endotext diagnostic tests diabetes insipidus copeptin water deprivation

Reading File
Browsing Directory

~/

Reading File
Reading File
Reading File
Reading File
Reading File
Generating Image

Medical educational diagram illustrating the hypothalamus, posterior pituitary, and kidney collecting duct in vasopressin water-balance physiology, labeled AVP pathway and aquaporin-2 water reabsorption

Generating Image

Medical educational infographic showing a diagnostic pathway for hypotonic polyuria, differentiating AVP deficiency, AVP resistance, and primary polydipsia using urine osmolality, serum sodium, copeptin, and desmopressin response

Running Command

mkdir -p "/tmp/workspace/diabetes-insipidus-presentation/assets" "/tmp/workspace/diabetes-insipidus-presentation/src" "/tmp/workspace/diabetes-insipidus-presentation/output" && python /tmp/skills/shared/scripts/fetch_images.py "https://cdn.orris.care/image-gen/ffba2cf7e46d4c868d4fd6c0386a1eca.png" "https://cdn.orris.care/image-gen/f5536a3ef25748ef8303ec80e09205f2.png" "https://cdn.orris.care/cdss_images/pmc_clinical_VQA_319acd259e60be6b8ac4f6c76f40da3d21935846d40bafc1f74c9fd285f2106f.jpg" > "/tmp/workspace/diabetes-insipidus-presentation/assets/fetched.json"

Reading File
Running Command

python -c "import json,base64,os; d=json.load(open('/tmp/workspace/diabetes-insipidus-presentation/assets/fetched.json')); names=['avp_pathway.png','diagnostic_pathway.png','pituitary_mri.jpg']; [open('/tmp/workspace/diabetes-insipidus-presentation/assets/'+n,'wb').write(base64.b64decode(x['base64'].split(',',1)[1])) for x,n in zip(d,names)]" && ls -la "/tmp/workspace/diabetes-insipidus-presentation/assets"

Running Command

python - <<'PY' from pathlib import Path p=Path('/tmp/workspace/diabetes-insipidus-presentation/src/create_deck.py') p.write_text(r'''from pptx import Presentation from pptx.util import Inches, Pt from pptx.dml.color import RGBColor from pptx.enum.shapes import MSO_SHAPE, MSO_CONNECTOR from pptx.enum.text import PP_ALIGN, MSO_ANCHOR from pptx.enum.dml import MSO_THEME_COLOR from pptx.enum.text import MSO_AUTO_SIZE from pptx.enum.shapes import MSO_SHAPE_TYPE from pptx.enum.text import MSO_ANCHOR from pptx import Presentation from pptx.util import Inches, Pt from pptx.dml.color import RGBColor from pptx.enum.shapes import MSO_SHAPE from pptx.enum.text import PP_ALIGN, MSO_ANCHOR OUT='/tmp/workspace/diabetes-insipidus-presentation/output/Understanding_and_Diagnosis_of_Diabetes_Insipidus.pptx' AS='/tmp/workspace/diabetes-insipidus-presentation/assets/' prs=Presentation(); prs.slide_width=Inches(13.333); prs.slide_height=Inches(7.5) blank=prs.slide_layouts[6] NAVY=RGBColor(10,31,56); BLUE=RGBColor(22,103,158); TEAL=RGBColor(16,148,139); CYAN=RGBColor(49,180,199); PALE=RGBColor(235,246,249); INK=RGBColor(31,50,67); MUTED=RGBColor(84,105,120); WHITE=RGBColor(255,255,255); RED=RGBColor(185,67,61); GOLD=RGBColor(223,159,44) def bg(slide, dark=False): sh=slide.background.fill; sh.solid(); sh.fore_color.rgb=NAVY if dark else RGBColor(250,253,254) # header bar r=slide.shapes.add_shape(MSO_SHAPE.RECTANGLE,0,0,Inches(13.333),Inches(.16)); r.fill.solid(); r.fill.fore_color.rgb=TEAL; r.line.fill.background() def textbox(slide,text,x,y,w,h,size=20,color=INK,bold=False,align=PP_ALIGN.LEFT): tb=slide.shapes.add_textbox(Inches(x),Inches(y),Inches(w),Inches(h)); tf=tb.text_frame; tf.clear(); tf.word_wrap=True; tf.margin_left=0;tf.margin_right=0;tf.margin_top=0;tf.margin_bottom=0; tf.vertical_anchor=MSO_ANCHOR.MIDDLE p=tf.paragraphs[0]; p.alignment=align; r=p.add_run(); r.text=text; r.font.name='Aptos';r.font.size=Pt(size);r.font.bold=bold;r.font.color.rgb=color return tb def title(slide,t,sub=None,dark=False): textbox(slide,t,.65,.38,12,.6,28,WHITE if dark else NAVY,True) if sub: textbox(slide,sub,.67,1.0,12,.35,12,RGBColor(190,220,230) if dark else MUTED) def footer(slide,n): textbox(slide,str(n),12.55,7.05,.35,.2,10,RGBColor(190,210,220),False,PP_ALIGN.RIGHT) def card(slide,x,y,w,h,head,body,accent=TEAL): s=slide.shapes.add_shape(MSO_SHAPE.ROUNDED_RECTANGLE, Inches(x), Inches(y), Inches(w), Inches(h));s.fill.solid();s.fill.fore_color.rgb=WHITE;s.line.color.rgb=RGBColor(214,228,234) a=slide.shapes.add_shape(MSO_SHAPE.RECTANGLE,Inches(x),Inches(y),Inches(.08),Inches(h));a.fill.solid();a.fill.fore_color.rgb=accent;a.line.fill.background() textbox(slide,head,x+.25,y+.18,w-.45,.32,16,NAVY,True) textbox(slide,body,x+.25,y+.62,w-.42,h-.75,12,INK) def bulletbox(slide,items,x,y,w,h,size=16,color=INK): tb=slide.shapes.add_textbox(Inches(x),Inches(y),Inches(w),Inches(h));tf=tb.text_frame;tf.clear();tf.word_wrap=True;tf.margin_left=0;tf.margin_top=0 for i,it in enumerate(items): p=tf.paragraphs[0] if i==0 else tf.add_paragraph();p.text=it;p.level=0;p.font.size=Pt(size);p.font.color.rgb=color;p.space_after=Pt(8) return tb def add_img(slide,path,x,y,w,h): slide.shapes.add_picture(path, Inches(x), Inches(y), width=Inches(w), height=Inches(h)) def flow(slide, labels, x=1.0,y=2.4,w=2.5,gap=.35, colors=None): for i,lab in enumerate(labels): xx=x+i*(w+gap); sh=slide.shapes.add_shape(MSO_SHAPE.ROUNDED_RECTANGLE,Inches(xx),Inches(y),Inches(w),Inches(1.0));sh.fill.solid();sh.fill.fore_color.rgb=(colors[i] if colors else PALE);sh.line.color.rgb=TEAL textbox(slide,lab,xx+.12,y+.14,w-.24,.72,15,NAVY,True,PP_ALIGN.CENTER) if i<len(labels)-1: textbox(slide,'›',xx+w+.08,y+.24,.18,.4,28,TEAL,True,PP_ALIGN.CENTER) # 1 s=prs.slides.add_slide(blank);bg(s,True);title(s,'Understanding and Diagnosis\nof Diabetes Insipidus','Modern approach to AVP disorders, hypotonic polyuria, and copeptin-based testing',True);add_img(s,AS+'avp_pathway.png',7.45,1.55,5.25,4.5);textbox(s,'Presentation deck | Medical / endocrine teaching',.7,6.68,5,.25,13,RGBColor(186,220,230));footer(s,1) #2 s=prs.slides.add_slide(blank);bg(s);title(s,'Learning objectives','By the end, the audience should be able to:'); for i,(h,b,a) in enumerate([('Recognize','Recognize hypotonic polyuria and identify clinical red flags.',TEAL),('Classify','Differentiate AVP deficiency, AVP resistance, and primary polydipsia.',BLUE),('Test','Apply a structured laboratory and dynamic-testing algorithm.',GOLD),('Investigate','Plan etiologic evaluation after the physiological diagnosis.',RED)]): card(s,.75+(i%2)*6.1,1.65+(i//2)*2.2,5.55,1.65,h,b,a) footer(s,2) #3 s=prs.slides.add_slide(blank);bg(s);title(s,'Core concept: failure to conserve water');add_img(s,AS+'avp_pathway.png',.65,1.55,6.25,4.9);card(s,7.25,1.55,5.35,1.3,'Normal AVP axis','Rising osmolality stimulates AVP release. AVP activates V2 receptors in the collecting duct and inserts aquaporin-2 water channels.',TEAL);card(s,7.25,3.05,5.35,1.3,'In diabetes insipidus','Either AVP secretion is inadequate or the kidney cannot respond. The result is dilute urine and compensatory thirst.',BLUE);card(s,7.25,4.55,5.35,1.3,'Modern language','AVP deficiency (AVP-D) replaces “central DI”; AVP resistance (AVP-R) replaces “nephrogenic DI”.',GOLD);footer(s,3) #4 s=prs.slides.add_slide(blank);bg(s);title(s,'What is diabetes insipidus?');card(s,.75,1.45,3.9,2.1,'Definition','A water-balance disorder causing large volumes of dilute urine due to impaired AVP secretion, AVP action, or increased AVP metabolism.',TEAL);card(s,4.75,1.45,3.9,2.1,'Physiological threshold','True hypotonic polyuria: 24-hour urine >50 mL/kg body weight with urine osmolality <300 mOsm/kg.',BLUE);card(s,8.75,1.45,3.9,2.1,'Why sodium may be normal','Intact thirst and ready access to water can compensate. Hypernatremia occurs when intake or thirst is impaired.',GOLD);textbox(s,'Key distinction: polyuria means increased volume, not simply urinary frequency.',.85,4.3,11.7,.5,21,NAVY,True,PP_ALIGN.CENTER);footer(s,4) #5 s=prs.slides.add_slide(blank);bg(s);title(s,'Clinical presentation and red flags');card(s,.75,1.4,3.85,3.9,'Typical symptoms','Polyuria\nPolydipsia, often preference for cold water\nNocturia\nFatigue and poor concentration',TEAL);card(s,4.75,1.4,3.85,3.9,'Examination / labs','Dehydration\nHigh-normal or high sodium\nRaised plasma osmolality\nInappropriately dilute urine',BLUE);card(s,8.75,1.4,3.85,3.9,'Urgent setting','Confusion, seizures, severe dehydration, hypernatremia, inability to drink, or new onset after pituitary surgery.',RED);textbox(s,'High sodium + dilute urine is a high-yield clue to DI.',.85,5.75,11.5,.4,19,RED,True,PP_ALIGN.CENTER);footer(s,5) #6 s=prs.slides.add_slide(blank);bg(s);title(s,'Classification and common causes'); card(s,.65,1.35,3.0,4.9,'AVP deficiency','Acquired: pituitary surgery, trauma, tumors, infiltrative or autoimmune disease.\n\nGenetic or idiopathic causes also occur.\n\nGestational form: placental vasopressinase increases AVP degradation.',TEAL) card(s,5.15,1.35,3.0,4.9,'AVP resistance','Acquired: lithium, hypercalcemia, hypokalemia, kidney disease, obstruction.\n\nGenetic: AVPR2 (often X-linked) or AQP2 mutations.',BLUE) card(s,9.65,1.35,3.0,4.9,'Primary polydipsia','Not DI. Excess water intake suppresses AVP.\n\nPsychiatric illness, compulsive drinking, dipsogenic disorders, or “health” water intake are contributors.',GOLD);footer(s,6) #7 s=prs.slides.add_slide(blank);bg(s);title(s,'Step 1: confirm hypotonic polyuria');flow(s,['History & 24-h urine','Urine osmolality','Exclude solute diuresis','Assess serum sodium'],.55,2.0,2.85,.28,[PALE,PALE,PALE,PALE]);card(s,.75,4.05,3.75,1.45,'History','Fluid intake, nocturia, medications, pregnancy, surgery or head injury, family history.',TEAL);card(s,4.8,4.05,3.75,1.45,'Basic laboratory tests','Na+, glucose, creatinine/eGFR, calcium, potassium, plasma osmolality, urinalysis.',BLUE);card(s,8.85,4.05,3.75,1.45,'Do not miss','Glycosuria, mannitol, diuretics, high urea load, recovery from AKI, chronic kidney disease.',GOLD);footer(s,7) #8 s=prs.slides.add_slide(blank);bg(s);title(s,'Step 2: interpret paired serum and urine osmolality'); card(s,.8,1.55,3.75,3.55,'High plasma osmolality / hypernatremia','If urine remains dilute or is submaximally concentrated, DI is strongly likely. Primary polydipsia is unlikely.',RED) card(s,4.8,1.55,3.75,3.55,'Normal plasma osmolality','Common in ambulatory DI because drinking matches urinary water losses. Dynamic testing is often needed.',BLUE) card(s,8.8,1.55,3.75,3.55,'Low or low-normal sodium','Primary polydipsia is more likely, but partial AVP-D can still require formal testing.',TEAL) textbox(s,'Interpret results in clinical context: thirst, access to water, renal function, and recent IV fluids all matter.',.85,5.7,11.5,.35,16,MUTED,False,PP_ALIGN.CENTER);footer(s,8) #9 s=prs.slides.add_slide(blank);bg(s);title(s,'Traditional dynamic test: water deprivation + desmopressin'); flow(s,['Supervised fluid restriction','Serial weight, vital signs, Na+ and Uosm','Give desmopressin','Measure Uosm response'],.45,1.65,3.0,.27,[PALE,PALE,PALE,PALE]); card(s,.75,3.55,3.75,2.0,'Primary polydipsia','Urine concentrates appropriately during deprivation, often to >500 mOsm/kg.',TEAL);card(s,4.8,3.55,3.75,2.0,'AVP deficiency','Persistently dilute urine then substantial rise after desmopressin. A rise >50% supports complete AVP-D.',BLUE);card(s,8.85,3.55,3.75,2.0,'AVP resistance','Little response to desmopressin. A rise <10% supports AVP-R. Values 10-50% are indeterminate.',RED);footer(s,9) #10 s=prs.slides.add_slide(blank);bg(s);title(s,'Why the water-deprivation test can be difficult'); card(s,.75,1.5,3.65,3.8,'Partial disorders','Partial AVP-D and partial AVP-R have overlapping urine osmolality responses.',GOLD);card(s,4.85,1.5,3.65,3.8,'Chronic polydipsia','Long-standing high water intake reduces medullary concentrating capacity and can mimic partial AVP-D.',BLUE);card(s,8.95,1.5,3.65,3.8,'Safety','The test requires supervision. Stop for weight loss, rising sodium, hypotension, tachycardia, or significant symptoms.',RED);footer(s,10) #11 s=prs.slides.add_slide(blank);bg(s);title(s,'Modern approach: copeptin');card(s,.75,1.42,4.0,1.35,'Why copeptin?','Copeptin is co-secreted with AVP in equimolar amounts but is analytically more stable than AVP.',TEAL);card(s,.75,3.0,4.0,1.35,'Baseline copeptin','A high baseline copeptin >21.4 pmol/L strongly identifies AVP resistance.',BLUE);card(s,.75,4.58,4.0,1.35,'Stimulated copeptin','After adequate hypertonic saline stimulation, low copeptin supports AVP deficiency; an appropriate rise supports primary polydipsia.',GOLD);add_img(s,AS+'diagnostic_pathway.png',5.15,1.25,7.2,4.95);footer(s,11) #12 s=prs.slides.add_slide(blank);bg(s);title(s,'Copeptin-based diagnostic interpretation'); flow(s,['Confirmed hypotonic polyuria','Baseline copeptin','If non-diagnostic: stimulated copeptin','Classify'],.45,1.3,3.0,.27,[PALE,PALE,PALE,PALE]); card(s,.75,3.0,3.75,2.25,'AVP resistance','Baseline copeptin >21.4 pmol/L strongly supports AVP-R.',BLUE);card(s,4.8,3.0,3.75,2.25,'AVP deficiency','Stimulated copeptin ≤4.9 pmol/L after adequate osmotic stimulation supports AVP-D.',RED);card(s,8.85,3.0,3.75,2.25,'Primary polydipsia','Stimulated copeptin >4.9 pmol/L at Na+ ≥150 mmol/L favors primary polydipsia.',TEAL);textbox(s,'Thresholds can vary with assay and local protocol. Testing requires specialist monitoring.',.8,5.85,11.7,.3,14,MUTED,False,PP_ALIGN.CENTER);footer(s,12) #13 s=prs.slides.add_slide(blank);bg(s);title(s,'Etiologic evaluation after confirming AVP deficiency');add_img(s,AS+'pituitary_mri.jpg',.65,1.4,5.3,4.55);textbox(s,'Example: stalk thickening and loss of posterior pituitary bright spot',.8,6.1,5.0,.35,12,MUTED,False,PP_ALIGN.CENTER);card(s,6.35,1.4,5.9,1.25,'MRI hypothalamus-pituitary with contrast','Look for pituitary stalk lesions, tumors, infiltrative disease, and postoperative changes.',TEAL);card(s,6.35,2.95,5.9,1.25,'Assess anterior pituitary function','Pituitary hormone deficiencies can coexist and may mask polyuria until glucocorticoid replacement is started.',BLUE);card(s,6.35,4.5,5.9,1.25,'Targeted history and tests','Trauma or surgery, malignancy, inflammatory disease, infection, sarcoidosis, Langerhans-cell histiocytosis, and genetic causes.',GOLD);footer(s,13) #14 s=prs.slides.add_slide(blank);bg(s);title(s,'Special clinical settings'); card(s,.75,1.45,3.75,3.9,'Post-pituitary surgery','Monitor fluid balance, urine output, sodium, and osmolality closely. Early postoperative DI may be transient; delayed hyponatremia can follow.',RED);card(s,4.8,1.45,3.75,3.9,'Pregnancy','Consider gestational AVP-D due to placental vasopressinase. Symptoms often begin in late pregnancy and improve after delivery.',GOLD);card(s,8.85,1.45,3.75,3.9,'Infants / impaired thirst','High risk of severe hypernatremia because they cannot reliably compensate with drinking. Treat as urgent.',BLUE);footer(s,14) #15 s=prs.slides.add_slide(blank);bg(s);title(s,'Exam-style summary algorithm');add_img(s,AS+'diagnostic_pathway.png',.7,1.25,6.1,4.9);card(s,7.25,1.35,5.25,1.05,'1. Confirm hypotonic polyuria','24-h volume + urine osmolality; exclude solute diuresis.',TEAL);card(s,7.25,2.65,5.25,1.05,'2. Check sodium / plasma osmolality','Hypernatremia with dilute urine makes DI highly likely.',BLUE);card(s,7.25,3.95,5.25,1.05,'3. Classify physiology','Use copeptin if available; otherwise supervised water deprivation plus desmopressin.',GOLD);card(s,7.25,5.25,5.25,1.05,'4. Investigate cause','MRI and pituitary assessment for AVP-D; medication and metabolic review for AVP-R.',RED);footer(s,15) #16 s=prs.slides.add_slide(blank);bg(s,True);title(s,'Take-home messages',None,True);bulletbox(s,['Use “AVP deficiency” and “AVP resistance” to describe the physiological defect.','Always confirm hypotonic polyuria and exclude osmotic diuresis before dynamic testing.','Hypernatremia or hyperosmolality with inappropriately dilute urine is strongly suggestive of DI.','Copeptin-based testing has improved differentiation of AVP-D from primary polydipsia.','Dynamic tests require monitoring, and etiologic investigation follows physiological classification.'],.9,1.55,11.4,4.6,21,WHITE);textbox(s,'Questions?',.9,6.5,11.4,.35,24,RGBColor(171,226,226),True,PP_ALIGN.CENTER);footer(s,16) #17 s=prs.slides.add_slide(blank);bg(s);title(s,'References'); refs=['Harrison’s Principles of Internal Medicine, 22nd ed. Chapter: Diabetes Insipidus (AVP Deficiency and AVP Resistance), 2025.','Brenner and Rector’s The Kidney. Differential Diagnosis of Polyuria.','Gubbi S, et al. Diagnostic Tests for Diabetes Insipidus. Endotext, updated 2025.','Refardt J, et al. Arginine- or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. N Engl J Med. 2023;389:1877-1887.','Ciortea DA, et al. Diagnostic Utility of Copeptin in Pediatric Patients with Polyuria-Polydipsia Syndrome: systematic review and meta-analysis. Int J Mol Sci. 2024;25:10743. PMID 39409072.','MRI slide image: medical image library figure demonstrating pituitary stalk thickening and absent posterior pituitary bright spot.'] bulletbox(s,refs,.85,1.35,11.7,5.6,15,INK);footer(s,17) prs.save(OUT) print(OUT) ''') PY python "/tmp/workspace/diabetes-insipidus-presentation/src/create_deck.py" && ls -lh "/tmp/workspace/diabetes-insipidus-presentation/output/Understanding_and_Diagnosis_of_Diabetes_Insipidus.pptx"

Running Command

python - <<'PY' from pptx import Presentation p='/tmp/workspace/diabetes-insipidus-presentation/output/Understanding_and_Diagnosis_of_Diabetes_Insipidus.pptx' prs=Presentation(p) print('slides',len(prs.slides)) for i,s in enumerate(prs.slides,1): texts=[] for sh in s.shapes: if getattr(sh,'has_text_frame',False) and sh.text_frame.text.strip(): texts.append(sh.text_frame.text.replace('\n',' | ')[:100]) pics=sum(1 for sh in s.shapes if sh.shape_type==13) print(i, 'pics',pics,'text:', ' || '.join(texts[:2])) PY

Created a 17-slide, exam-oriented PowerPoint on Understanding and Diagnosis of Diabetes Insipidus. It includes:
  • AVP physiology and modern terminology
  • AVP deficiency, AVP resistance, and primary polydipsia
  • Clinical features and red flags
  • Stepwise diagnostic approach
  • Water-deprivation and desmopressin interpretation
  • Modern copeptin-based testing
  • Pituitary MRI example and etiologic evaluation
  • Diagnostic algorithms, suitable medical images, and references

Understanding and Diagnosis of Diabetes Insipidus

Presentation · PPTX

Pptx should not be done or look like done by AI it should be neat and should look like creative presentation not AI done plz

Reading File
Reading File
Browsing Directory

~/diabetes-insipidus-presentation

Reading File
Running Command

python - <<'PY' from pathlib import Path p=Path('/tmp/workspace/diabetes-insipidus-presentation/src/create_creative_deck.py') p.write_text(r'''from pptx import Presentation from pptx.util import Inches, Pt from pptx.dml.color import RGBColor from pptx.enum.shapes import MSO_SHAPE from pptx.enum.text import PP_ALIGN, MSO_ANCHOR from pptx.enum.dml import MSO_LINE_DASH_STYLE OUT='/tmp/workspace/diabetes-insipidus-presentation/output/Diabetes_Insipidus_Creative_Presentation.pptx' MRI='/tmp/workspace/diabetes-insipidus-presentation/assets/pituitary_mri.jpg' prs=Presentation(); prs.slide_width=Inches(13.333); prs.slide_height=Inches(7.5); blank=prs.slide_layouts[6] # warm editorial medical palette INK=RGBColor(28,42,53); INK2=RGBColor(56,73,83); SAGE=RGBColor(84,123,119); MINT=RGBColor(215,235,229); PAPER=RGBColor(248,246,240); WHITE=RGBColor(255,255,255); CLAY=RGBColor(196,105,77); SAND=RGBColor(235,222,197); BLUE=RGBColor(65,117,143); PALEBLUE=RGBColor(218,232,239); RED=RGBColor(174,67,61); GREY=RGBColor(126,139,144) def rect(slide,x,y,w,h,fill, line=None, radius=False): sh=slide.shapes.add_shape(MSO_SHAPE.ROUNDED_RECTANGLE if radius else MSO_SHAPE.RECTANGLE, Inches(x), Inches(y), Inches(w), Inches(h)) sh.fill.solid(); sh.fill.fore_color.rgb=fill if line: sh.line.color.rgb=line else: sh.line.fill.background() return sh def tx(slide,text,x,y,w,h,sz=18,color=INK,bold=False,align=PP_ALIGN.LEFT,font='Aptos Display'): box=slide.shapes.add_textbox(Inches(x),Inches(y),Inches(w),Inches(h)); tf=box.text_frame;tf.clear();tf.word_wrap=True;tf.margin_left=0;tf.margin_right=0;tf.margin_top=0;tf.margin_bottom=0;tf.vertical_anchor=MSO_ANCHOR.MIDDLE p=tf.paragraphs[0];p.alignment=align;r=p.add_run();r.text=text;r.font.name=font;r.font.size=Pt(sz);r.font.bold=bold;r.font.color.rgb=color return box def lines(slide, items, x,y,w, sz=16, color=INK2, gap=9): box=slide.shapes.add_textbox(Inches(x), Inches(y), Inches(w), Inches(5.3)); tf=box.text_frame;tf.clear();tf.word_wrap=True;tf.margin_left=0;tf.margin_top=0 for i,item in enumerate(items): p=tf.paragraphs[0] if i==0 else tf.add_paragraph();p.text=item;p.font.name='Aptos';p.font.size=Pt(sz);p.font.color.rgb=color;p.space_after=Pt(gap) return box def base(slide,no,section='UNDERSTANDING & DIAGNOSIS'): slide.background.fill.solid();slide.background.fill.fore_color.rgb=PAPER rect(slide,.56,.42,.13,.13,SAGE) tx(slide,section,.78,.35,4,.28,9,SAGE,True,font='Aptos') tx(slide,f'{no:02d}',12.25,6.88,.45,.23,10,GREY,False,PP_ALIGN.RIGHT,font='Aptos') def h(slide,title,kicker=None): if kicker: tx(slide,kicker,.78,1.12,11.4,.25,10,CLAY,True,font='Aptos') tx(slide,title,.75,1.38,11.7,.68,29,INK,True) def dot(slide,x,y,color=SAGE,scale=.12): rect(slide,x,y,scale,scale,color, radius=True) def rule(slide,x,y,w,color=RGBColor(207,211,205)): rect(slide,x,y,w,.015,color) #1 Cover s=prs.slides.add_slide(blank);s.background.fill.solid();s.background.fill.fore_color.rgb=INK rect(s,0,0,13.333,7.5,INK);rect(s,.72,.82,.18,.18,CLAY,True) tx(s,'DIABETES\nINSIPIDUS',.73,1.35,6.3,1.65,37,WHITE,True) tx(s,'Understanding the AVP axis\nand making the diagnosis with confidence',.78,3.42,5.4,.7,17,RGBColor(211,226,220),False,font='Aptos') rule(s,.78,4.55,4.65,RGBColor(102,135,131));tx(s,'A focused clinical presentation',.78,4.75,4,.28,12,RGBColor(194,213,207),False,font='Aptos') # minimalist kidney/pituitary motif for i,(x,y,r,c) in enumerate([(9.0,1.45,1.2,SAGE),(10.15,2.65,.58,CLAY),(9.0,4.3,.45,RGBColor(119,168,163)),(11.0,4.25,.86,BLUE)]): sh=s.shapes.add_shape(MSO_SHAPE.OVAL,Inches(x), Inches(y), Inches(r), Inches(r));sh.fill.solid();sh.fill.fore_color.rgb=c;sh.line.fill.background() tx(s,'AVP',9.02,1.75,1.15,.35,19,WHITE,True,PP_ALIGN.CENTER);tx(s,'H₂O',10.18,2.82,.5,.22,11,WHITE,True,PP_ALIGN.CENTER);tx(s,'kidney',10.95,4.57,.96,.2,11,WHITE,True,PP_ALIGN.CENTER) #2 s=prs.slides.add_slide(blank);base(s,2,'THE CLINICAL QUESTION');h(s,'When does polyuria mean “DI”?','START WITH THE PHENOTYPE') tx(s,'Polyuria is a volume problem, not a frequency problem.',.78,2.33,7.5,.38,20,SAGE,True) lines(s,['Measure 24-hour urine output before ordering dynamic tests.','Confirm hypotonic urine, then determine whether AVP secretion or renal response is impaired.','Think of DI as a disorder of water conservation.'],.83,3.05,6.3,18) rect(s,8.1,2.18,3.85,2.85,MINT,None,True);tx(s,'TRUE HYPOTONIC\nPOLYURIA',8.43,2.62,3.15,.55,17,INK,True,PP_ALIGN.CENTER);tx(s,'Urine volume >50 mL/kg/day\n+ urine osmolality <300 mOsm/kg',8.43,3.48,3.15,.65,18,SAGE,True,PP_ALIGN.CENTER);tx(s,'The starting point for diagnosis',8.43,4.45,3.15,.24,11,INK2,False,PP_ALIGN.CENTER,font='Aptos') #3 s=prs.slides.add_slide(blank);base(s,3,'PHYSIOLOGY');h(s,'The AVP pathway in one slide','WHY URINE CONCENTRATES') # editorial horizontal story stages=[('1','Osmoreceptors','Rising plasma osmolality'),('2','Posterior pituitary','AVP is released'),('3','Collecting duct','V2 receptor activation'),('4','Aquaporin-2','Water is reabsorbed')] for i,(n,hd,bd) in enumerate(stages): x=.75+i*3.13 rect(s,x,2.55,2.48,2.15,WHITE,RGBColor(220,219,213),True);tx(s,n,x+.2,2.76,.35,.3,14,CLAY,True);tx(s,hd,x+.2,3.17,2.04,.3,16,INK,True);tx(s,bd,x+.2,3.72,2.0,.5,13,INK2,False,font='Aptos') if i<3: tx(s,'→',x+2.58,3.33,.35,.3,22,SAGE,True,PP_ALIGN.CENTER) rect(s,.75,5.42,11.8,.55,INK,None,True);tx(s,'Failure at the pituitary = AVP deficiency | Failure at the kidney = AVP resistance',.98,5.55,11.3,.22,14,WHITE,True,PP_ALIGN.CENTER,font='Aptos') #4 s=prs.slides.add_slide(blank);base(s,4,'LANGUAGE & CLASSIFICATION');h(s,'Three mechanisms. One shared phenotype.','CLASSIFY BEFORE YOU TEST') cols=[('AVP deficiency','Inadequate synthesis or release of AVP.\nFormerly “central DI”.',SAGE),('AVP resistance','The collecting duct does not respond to AVP.\nFormerly “nephrogenic DI”.',BLUE),('Primary polydipsia','Excess water intake suppresses AVP.\nA mimic, not DI.',CLAY)] for i,(a,b,c) in enumerate(cols): x=.75+i*4.1;rect(s,x,2.1,3.6,2.9,WHITE,None,True);rect(s,x,2.1,3.6,.12,c);tx(s,a,x+.3,2.62,3,.35,20,INK,True);tx(s,b,x+.3,3.35,2.95,.9,15,INK2,False,font='Aptos');tx(s,'Clinical question →',x+.3,4.47,1.5,.2,10,c,True,font='Aptos') tx(s,'Can the body make AVP? Can the kidney answer it? Or is water intake driving the picture?',.78,5.72,11.7,.35,18,SAGE,True,PP_ALIGN.CENTER) #5 s=prs.slides.add_slide(blank);base(s,5,'CLINICAL RECOGNITION');h(s,'Read the bedside clues first','THE PATTERN MATTERS') rect(s,.75,2.05,5.1,3.55,WHITE,None,True);tx(s,'Typical history',1.12,2.42,2.5,.35,19,INK,True);lines(s,['Polyuria and nocturia','Persistent thirst, often cold water preference','Recent pituitary surgery, trauma, pregnancy or lithium exposure'],1.12,3.05,4.2,16) rect(s,6.22,2.05,5.1,3.55,INK,None,True);tx(s,'Red flags',6.6,2.42,2.5,.35,19,WHITE,True);lines(s,['Hypernatremia or rising osmolality','Confusion, weakness or dehydration','Unable to drink, reduced consciousness, infants or frail patients'],6.6,3.05,4.2,16,RGBColor(220,235,230)) rect(s,1.1,5.95,10.6,.06,CLAY);tx(s,'A normal sodium does not exclude DI when thirst and water access are intact.',1.1,6.2,10.7,.25,15,INK2,True,PP_ALIGN.CENTER,font='Aptos') #6 s=prs.slides.add_slide(blank);base(s,6,'FIRST-LINE WORK-UP');h(s,'Before dynamic testing: confirm, pair, exclude','A SIMPLE FOUR-PART PANEL') items=[('01','Confirm volume','24-hour urine output'),('02','Pair osmolality','Serum Na+/plasma osmolality + Uosm'),('03','Exclude solute diuresis','Glucose, urinalysis, renal function'),('04','Correct reversible drivers','K+, Ca2+, medications, obstruction')] for i,(n,a,b) in enumerate(items): y=2.1+i*1.0;tx(s,n,.85,y,.5,.25,12,CLAY,True);tx(s,a,1.55,y,3.2,.28,17,INK,True);tx(s,b,5.0,y,5.8,.28,15,INK2,False,font='Aptos');rule(s,1.55,y+.56,9.25) #7 s=prs.slides.add_slide(blank);base(s,7,'INTERPRETATION');h(s,'Pair serum sodium with urine osmolality','THE FIRST FORK IN THE ROAD') rect(s,.75,2.1,3.75,3.15,PALEBLUE,None,True);tx(s,'High Na+ / high plasma osmolality',1.08,2.5,3.1,.6,18,INK,True,PP_ALIGN.CENTER);tx(s,'+ dilute urine\n\nDI is strongly likely',1.08,3.45,3.1,.9,17,BLUE,True,PP_ALIGN.CENTER) rect(s,4.8,2.1,3.75,3.15,MINT,None,True);tx(s,'Normal Na+ / normal osmolality',5.13,2.5,3.1,.6,18,INK,True,PP_ALIGN.CENTER);tx(s,'Thirst may be compensating\n\nProceed to formal testing',5.13,3.45,3.1,.9,17,SAGE,True,PP_ALIGN.CENTER) rect(s,8.85,2.1,3.75,3.15,SAND,None,True);tx(s,'Low or low-normal Na+',9.18,2.5,3.1,.6,18,INK,True,PP_ALIGN.CENTER);tx(s,'Primary polydipsia more likely\n\nbut partial DI may overlap',9.18,3.45,3.1,.9,17,CLAY,True,PP_ALIGN.CENTER) #8 s=prs.slides.add_slide(blank);base(s,8,'CLASSIC TEST');h(s,'Water deprivation plus desmopressin','THE ESTABLISHED PATHWAY') # timeline for i,(a,b,c) in enumerate([('Restrict','Supervised fluid restriction',SAGE),('Monitor','Weight, vitals, Na+ and Uosm',BLUE),('Administer','Desmopressin',CLAY),('Interpret','Change in Uosm',INK)]): x=.75+i*3.05;dot(s,x+1.05,2.43,c,.23);tx(s,a,x,2.85,2.35,.28,17,INK,True,PP_ALIGN.CENTER);tx(s,b,x+.1,3.3,2.15,.45,13,INK2,False,PP_ALIGN.CENTER,font='Aptos') if i<3: rect(s,x+2.2,2.52,.85,.035,RGBColor(184,198,194)) rect(s,.75,4.47,11.8,1.18,WHITE,None,True);tx(s,'Interpretation',1.05,4.76,1.5,.28,16,CLAY,True);tx(s,'>50% rise in Uosm → AVP deficiency | <10% rise → AVP resistance | intermediate results → overlap',2.55,4.76,9.5,.3,15,INK,True,PP_ALIGN.CENTER,font='Aptos') tx(s,'Perform only with clinical supervision and predefined stop criteria.',.8,6.15,11.6,.25,13,RED,True,PP_ALIGN.CENTER,font='Aptos') #9 s=prs.slides.add_slide(blank);base(s,9,'MODERN TESTING');h(s,'Copeptin changes the diagnostic conversation','A STABLE SURROGATE FOR AVP') rect(s,.75,2.08,4.2,3.65,INK,None,True);tx(s,'Why copeptin?',1.1,2.55,3.2,.35,21,WHITE,True);lines(s,['Released in equimolar amounts with AVP.','More stable and easier to measure than AVP.','Useful when traditional testing is equivocal.'],1.1,3.22,3.25,16,RGBColor(221,235,231),10) rect(s,5.35,2.08,6.65,1.42,WHITE,None,True);tx(s,'Baseline copeptin >21.4 pmol/L',5.72,2.47,3.3,.32,18,BLUE,True);tx(s,'Strongly supports AVP resistance.',9.02,2.47,2.5,.32,14,INK2,False,font='Aptos') rect(s,5.35,3.9,6.65,1.42,WHITE,None,True);tx(s,'Stimulated copeptin',5.72,4.26,2.4,.32,18,SAGE,True);tx(s,'Low after osmotic stimulation supports AVP-D; an appropriate rise supports primary polydipsia.',8.15,4.12,3.25,.62,13,INK2,False,font='Aptos') #10 s=prs.slides.add_slide(blank);base(s,10,'COPEPTIN ALGORITHM');h(s,'Use the result to classify the physiology','PREFERRED WHEN AVAILABLE') # decision tree native rect(s,.75,2.0,2.5,.78,INK,None,True);tx(s,'Confirmed hypotonic\npolyuria',.9,2.17,2.2,.36,16,WHITE,True,PP_ALIGN.CENTER) tx(s,'→',3.35,2.18,.4,.3,24,SAGE,True,PP_ALIGN.CENTER) rect(s,3.85,2.0,2.45,.78,MINT,None,True);tx(s,'Baseline copeptin',4.05,2.22,2.05,.26,16,INK,True,PP_ALIGN.CENTER) tx(s,'→',6.42,2.18,.4,.3,24,SAGE,True,PP_ALIGN.CENTER) rect(s,6.92,2.0,2.6,.78,PALEBLUE,None,True);tx(s,'Stimulate if needed',7.16,2.22,2.1,.26,16,INK,True,PP_ALIGN.CENTER) rect(s,1.05,4.18,3.25,1.35,WHITE,None,True);tx(s,'>21.4 pmol/L',1.35,4.5,2.65,.28,18,BLUE,True,PP_ALIGN.CENTER);tx(s,'AVP resistance',1.35,4.94,2.65,.23,14,INK2,False,PP_ALIGN.CENTER,font='Aptos') rect(s,5.05,4.18,3.25,1.35,WHITE,None,True);tx(s,'≤4.9 pmol/L after stimulation',5.27,4.5,2.8,.28,16,RED,True,PP_ALIGN.CENTER);tx(s,'AVP deficiency',5.35,4.94,2.65,.23,14,INK2,False,PP_ALIGN.CENTER,font='Aptos') rect(s,9.05,4.18,3.25,1.35,WHITE,None,True);tx(s,'>4.9 pmol/L after stimulation',9.27,4.5,2.8,.28,16,SAGE,True,PP_ALIGN.CENTER);tx(s,'Primary polydipsia favored',9.35,4.94,2.65,.23,14,INK2,False,PP_ALIGN.CENTER,font='Aptos') for x in [2.6,6.6,10.6]: rect(s,x,3.05,.035,1.1,RGBColor(183,195,190)) tx(s,'Hypertonic saline stimulation needs specialist supervision and serial sodium measurement.',.8,6.18,11.5,.25,13,RED,True,PP_ALIGN.CENTER,font='Aptos') #11 s=prs.slides.add_slide(blank);base(s,11,'AFTER AVP DEFICIENCY');h(s,'Then ask: what is affecting the hypothalamic-pituitary axis?','ETIOLOGIC WORK-UP') s.shapes.add_picture(MRI, Inches(.75), Inches(2.05), width=Inches(4.75), height=Inches(3.85));tx(s,'MRI example: stalk thickening with absent posterior “bright spot”',.78,6.08,4.8,.32,10,GREY,False,font='Aptos') rect(s,6.05,2.05,5.75,1.0,WHITE,None,True);tx(s,'MRI with contrast',6.4,2.36,2.2,.28,17,SAGE,True);tx(s,'Sellar / suprasellar mass, stalk lesion, infiltrative disease',8.45,2.36,2.9,.3,13,INK2,False,font='Aptos') rect(s,6.05,3.43,5.75,1.0,WHITE,None,True);tx(s,'Anterior pituitary profile',6.4,3.74,2.55,.28,17,BLUE,True);tx(s,'Coexisting hormone deficits can mask DI',9.05,3.74,2.25,.3,13,INK2,False,font='Aptos') rect(s,6.05,4.81,5.75,1.0,WHITE,None,True);tx(s,'Targeted history',6.4,5.12,2.0,.28,17,CLAY,True);tx(s,'Surgery, trauma, tumor, autoimmune or infiltrative disease',8.45,5.12,2.9,.3,13,INK2,False,font='Aptos') #12 s=prs.slides.add_slide(blank);base(s,12,'SPECIAL SETTINGS');h(s,'Some patients cannot compensate with thirst','WHERE DI BECOMES DANGEROUS') for i,(a,b,c) in enumerate([('After pituitary surgery','Track input/output and sodium. DI may be transient; later hyponatremia can occur.',RED),('Pregnancy','Placental vasopressinase can cause gestational AVP deficiency, often resolving postpartum.',CLAY),('Infants & impaired thirst','Limited access to water or absent thirst makes hypernatremia a medical emergency.',BLUE)]): x=.75+i*4.1;rect(s,x,2.25,3.55,3.15,WHITE,None,True);rect(s,x,2.25,3.55,.11,c);tx(s,a,x+.28,2.8,2.9,.55,19,INK,True);tx(s,b,x+.28,3.8,2.85,.85,14,INK2,False,font='Aptos') #13 s=prs.slides.add_slide(blank);base(s,13,'FINAL SLIDE');h(s,'Five lines to remember','TAKE-HOME MESSAGE') notes=['Confirm hypotonic polyuria before naming DI.','Hypernatremia plus dilute urine makes DI very likely.','Use copeptin to clarify AVP deficiency versus primary polydipsia when available.','Use water deprivation and desmopressin only under supervision.','Once physiology is classified, investigate the cause.'] for i,n in enumerate(notes): y=2.05+i*.77;dot(s,.93,y+.13,CLAY,.16);tx(s,n,1.3,y,10.5,.32,18,INK,True) tx(s,'Thank you',.78,6.48,11.5,.34,22,SAGE,True,PP_ALIGN.CENTER) #14 References s=prs.slides.add_slide(blank);base(s,14,'REFERENCES');h(s,'Selected sources','FOR FURTHER READING') refs=['Harrison’s Principles of Internal Medicine, 22nd ed. Diabetes Insipidus (AVP Deficiency and AVP Resistance). 2025.','Brenner and Rector’s The Kidney. Differential Diagnosis of Polyuria.','Gubbi S, et al. Diagnostic Tests for Diabetes Insipidus. Endotext, updated 2025.','Refardt J, et al. Arginine- or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. N Engl J Med. 2023;389:1877-1887.','Ciortea DA, et al. Diagnostic Utility of Copeptin in Pediatric Polyuria-Polydipsia Syndrome. Int J Mol Sci. 2024;25:10743. PMID 39409072.'] lines(s,refs,.85,2.15,11.35,16,INK2,14) tx(s,'Design note: visual structure is intentionally restrained to keep the slides presenter-led and clinically credible.',.85,6.15,11.2,.25,11,GREY,False,PP_ALIGN.CENTER,font='Aptos') prs.save(OUT);print(OUT) ''') PY python "/tmp/workspace/diabetes-insipidus-presentation/src/create_creative_deck.py" && ls -lh "/tmp/workspace/diabetes-insipidus-presentation/output/Diabetes_Insipidus_Creative_Presentation.pptx"

Running Command

python - <<'PY' p='/tmp/workspace/diabetes-insipidus-presentation/src/create_creative_deck.py' s=open(p).read() s=s.replace("rect(s,.72,.82,.18,.18,CLAY,True)","rect(s,.72,.82,.18,.18,CLAY,None,True)") open(p,'w').write(s) PY python "/tmp/workspace/diabetes-insipidus-presentation/src/create_creative_deck.py" && ls -lh "/tmp/workspace/diabetes-insipidus-presentation/output/Diabetes_Insipidus_Creative_Presentation.pptx"

Running Command

python - <<'PY' from pptx import Presentation p='/tmp/workspace/diabetes-insipidus-presentation/output/Diabetes_Insipidus_Creative_Presentation.pptx' prs=Presentation(p) print('slides:', len(prs.slides)) for i,s in enumerate(prs.slides,1): texts=[sh.text_frame.text.replace('\n',' | ') for sh in s.shapes if getattr(sh,'has_text_frame',False) and sh.text_frame.text.strip()] pics=sum(sh.shape_type==13 for sh in s.shapes) print(i, 'pictures=',pics,'shapes=',len(s.shapes),'title=',texts[1][:75] if len(texts)>1 else texts[0][:75]) PY

I redesigned it as a cleaner, more presenter-led deck with:
  • Editorial medical styling rather than repetitive template cards
  • Restrained color palette and more whitespace
  • Shorter, natural slide text and better slide pacing
  • Native visual flow diagrams and a focused MRI slide
  • 14 polished slides suitable for a classroom or clinical presentation

Diabetes Insipidus Creative Presentation

Presentation · PPTX

This is a shared conversation. Sign in to Orris to start your own chat.